Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nogra Pharma Ltd.

www.giulianipharma.com

Latest From Nogra Pharma Ltd.

Celgene Notches A Needed Win As Acceleron-Partnered Luspatercept Succeeds In MDS

Celgene delivers positive top-line Phase III results for a key pipeline drug as luspatercept reduces the need for blood transfusions in patients with myelodysplastic syndromes. Partner Acceleron's stock soars ahead of a detailed data presentation later this year.

Clinical Trials Blood & Coagulation Disorders

Celgene Shares Good News On Ozanimod, Quietly Dumps Pricey GED-0301

Strong Q1 results and a plan to refile ozanimod in early 2019 may help investors regain confidence in Celgene, but a lot depends on the company's pipeline, which had an additional setback with discontinuation of all GED-0301 development.

Sales & Earnings Business Strategies

Celgene's Terrie Curran On Building, Broadening The I&I Franchise

Celgene has hit multiple roadblocks in building its inflammation and immunology (I&I) portfolio, but it has a lot of potential shots on goal to eventually help the company diversify its revenue beyond the cancer blockbuster Revlimid, starting with flagship product Otezla.

Business Strategies Immune Disorders

More Bad News: Celgene Reveals Refuse-To-File Letter For Ozanimod In MS

Celgene said the US FDA issued a refuse-to-file letter for ozanimod in multiple sclerosis because "the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a review." It's yet another big blow for a company whose value has been falling since October.

Business Strategies Neurology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • Giuliani SPA
  • Giuliani International SPA
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Nogra Pharma Ltd.
  • Senior Management
  • Contact Info
  • Nogra Pharma Ltd.
    Phone: (39) 1 6731827
    33 Sir John Rogersons Quay
    Dublin, 24
    Ireland
Advertisement
Advertisement
UsernamePublicRestriction

Register